Unknown

Dataset Information

0

Improved Characteristics of RANKL Immuno-PET Imaging Using Radiolabeled Antibody Fab Fragments.


ABSTRACT:

Purpose

RANKL expression in the tumor microenvironment has been identified as a biomarker of immune suppression, negating the effect of some cancer immunotherapies. Previously we had developed a radiotracer based on the FDA-approved RANKL-specific antibody denosumab, [89Zr]Zr-DFO-denosumab, enabling successful immuno-PET imaging. Radiolabeled denosumab, however, showed long blood circulation and delayed tumor uptake, potentially limiting its applications. Here we aimed to develop a smaller radiolabeled denosumab fragment, [64Cu]Cu-NOTA-denos-Fab, that would ideally show faster tumor accumulation and better diffusion into the tumor for the visualization of RANKL.

Experimental design

Fab fragments were prepared from denosumab using papain and conjugated to a NOTA chelator for radiolabeling with 64Cu. The bioconjugates were characterized in vitro using SDS-PAGE analysis, and the binding affinity was assessed using a radiotracer cell binding assay. Small animal PET imaging evaluated tumor targeting and biodistribution in transduced RANKL-ME-180 xenografts.

Results

The radiolabeling yield of [64Cu]Cu-NOTA-denos-Fab was 58 ± 9.2%, with a specific activity of 0.79 ± 0.11 MBq/µg (n = 3). A radiotracer binding assay proved specific targeting of RANKL in vitro. PET imaging showed fast blood clearance and high tumor accumulation as early as 1 h p.i. (2.14 ± 0.21% ID/mL), which peaked at 5 h p.i. (2.72 ± 0.61% ID/mL). In contrast, [64Cu]Cu-NOTA-denosumab reached its highest tumor uptake at 24 h p.i. (6.88 ± 1.12% ID/mL). [64Cu]Cu-NOTA-denos-Fab specifically targeted human RANKL in transduced ME-180 xenografts compared with the blocking group and negative ME-180 xenograft model. Histological analysis confirmed RANKL expression in RANKL-ME-180 xenografts.

Conclusions

Here, we report on a novel RANKL PET imaging agent, [64Cu]Cu-NOTA-denos-Fab, that allows for fast tumor imaging with improved imaging contrast when compared with its antibody counterpart, showing promise as a potential PET RANKL imaging tool for future clinical applications.

SUBMITTER: Dewulf J 

PROVIDER: S-EPMC9147590 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Improved Characteristics of RANKL Immuno-PET Imaging Using Radiolabeled Antibody Fab Fragments.

Dewulf Jonatan J   Hrynchak Ivanna I   Geudens Sarah S   Pintelon Isabel I   Vangestel Christel C   Sereno José J   van Dam Peter A PA   Abrunhosa Antero J AJ   Elvas Filipe F   Van den Wyngaert Tim T  

Pharmaceutics 20220426 5


<h4>Purpose</h4>RANKL expression in the tumor microenvironment has been identified as a biomarker of immune suppression, negating the effect of some cancer immunotherapies. Previously we had developed a radiotracer based on the FDA-approved RANKL-specific antibody denosumab, [<sup>89</sup>Zr]Zr-DFO-denosumab, enabling successful immuno-PET imaging. Radiolabeled denosumab, however, showed long blood circulation and delayed tumor uptake, potentially limiting its applications. Here we aimed to deve  ...[more]

Similar Datasets

| S-EPMC8124205 | biostudies-literature
| S-EPMC3903195 | biostudies-literature
| S-EPMC4161125 | biostudies-literature
| S-EPMC5800945 | biostudies-literature
| S-EPMC6785789 | biostudies-literature
| S-EPMC5841805 | biostudies-literature
| S-EPMC4622060 | biostudies-literature
| S-EPMC4452422 | biostudies-literature
| S-EPMC9147562 | biostudies-literature
| S-EPMC5362313 | biostudies-literature